For the quarter ending 2025-09-30, IMNM had $129,398K increase in cash & cash equivalents over the period. -$148,652K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -142,494 | - |
| Depreciation and amortization | 1,837 | - |
| Amortization of right-of-use asset | 342 | - |
| Accretion of discounts on marketable securities | 2,839 | - |
| Share-based compensation expense | 17,797 | - |
| Loss on disposal of property and equipment | -841 | - |
| Charge for purchase of in-process research and development assets | 0 | - |
| Prepaid expenses and other assets | 3,447 | - |
| Accounts payable | -6,887 | - |
| Accrued expenses and other current liabilities | -1,167 | - |
| Deferred revenue | -6,941 | - |
| Operating lease liabilities | -8 | - |
| Net cash used in operating activities | -142,966 | - |
| Purchases of in-process research and development assets | 6,246 | - |
| Purchases of marketable securities | 123,266 | - |
| Maturities of marketable securities | 200,000 | - |
| Purchases of property and equipment | 5,686 | - |
| Net cash provided by (used in) investing activities | 64,802 | - |
| Proceeds from public offering | 172,500 | - |
| Proceeds from issuance of common stock under atm | 45,897 | - |
| Payment of offering costs | 11,674 | - |
| Proceeds from exercise of stock options | 839 | - |
| Proceeds from exercise of common stock warrants | 0 | - |
| Net cash provided by financing activities | 207,562 | - |
| Net increase in cash and cash equivalents and restricted cash | 129,398 | - |
| Cash and cash equivalents | - | 143,876 |
| Cash and cash equivalents at beginning of period | 143,451 | - |
| Cash and cash equivalents at end of period | 272,849 | 144,086 |
Immunome Inc. (IMNM)
Immunome Inc. (IMNM)